Andere Sprachen Scinai Immunotherapeutics Ltd.

Aktien

A3DZ0C

US09073Q2049

SCNI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 24.04.2024			% 5 Tage	% 1. Jan.
0.4724 ^USD	-2.15%		+5.47%	-20.66%

08.04.	Börsengehandelte Fonds und Aktienfutures legen vor dem Glockenschlag am Montag leicht zu, da die Wahrscheinlichkeit einer Zinssenkung im Juni sinkt	MT
08.04.	Ayana Pharma wählt die CDMO-Einheit von Scinai Immunotherapeutics für die Entwicklung und cGMP-Herstellung von Arzneimitteln	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Scinai Immunotherapeutics CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services	09.04.
Exchange-Traded Funds, Equity Futures Gain Slightly Pre-Bell Monday as June Rate Cut Likelihood Falls	08.04.
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services	08.04.
Ayana Pharma Selects Scinai Immunotherapeutics' CDMO Unit to Provide Drug Development and cGMP Manufacturing Services	08.04.
Scinai leadership to attend BIO-Europe Spring 2024	12.03.
Scinai Immunotherapeutics to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024	01.03.
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024	29.02.
Scinai Welcomes Liat Halpert as Head of Business Development and Sales	13.02.
Scinai Immunotherapeutics Ltd. Appoints Liat Halpert as Head of Business Development and Sales	13.02.
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Gorlich on Louis-Jeantet Prize	26.01.
Scinai Immunotherapeutics Ltd. announced that it has received $1.694259 million in funding	12.01.
Scinai Immunotherapeutics CEO Issues Letter to Shareholders	04.01.
Scinai Immunotherapeutics Exercises Outstanding Warrants for $1.69 Million in Proceeds	29.12.
Scinai Immunotherapeutics Ltd. announced that it expects to receive $1.694259 million in funding	29.12.
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9	27.12.
Scinai Announces Promising Results in a Psoriatic Human Skin Model	12.12.
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics coronavirus NanoAb as aerosolized prophylactic and therapeutic drug	12.12.
Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug	11.12.
European Investment Bank extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031	30.11.
European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031	29.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Scinai Immunotherapeutics Ltd.

Aktien

A3DZ0C

US09073Q2049

SCNI

Andere Sprachen

Filter